Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders
Moratorium Goes Into Effect After Market Close on March 13, 2023
NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL, March 13, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Todos Medical, Ltd. (OTCQB:TOMDF), a comprehensive medical diagnostics and related solutions company, today announced the Company has entered into a new agreement with holders of its convertible notes that provides for a 21-day moratorium on conversion of those convertible notes. Strategic investor Yozma Group Korea (“Yozma”) has not converted any securities. The Company’s objective is to find the optimum path that balances the immediate capital requirements with a balanced plan that moves the Company forward and maintains its OTCQB listing requirement over $.001. This agreement is designed to provide sufficient time for the Company to negotiate a new financing agreement with its existing noteholders in order to help finance the Company’s ongoing operations and certain key strategic transactions.
Related news for (TOMDF)
- Todos Medical Announces Insolvency Proceedings in Israel
- Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
- Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
- Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
- Todos Medical Begins Trading on the OTC Pink Marketplace